Evaluation of the anti-Acanthamoeba activity of two commercial eye drops commonly used to lower eye pressure

Evaluation of the anti-Acanthamoeba activity of two commercial eye drops commonly used to lower eye pressure

Accepted Manuscript Evaluation of the anti-Acanthamoeba activity of two commercial eye drops commonly used to lower eye pressure Ines Sifaoui, María R...

6MB Sizes 1 Downloads 16 Views

Accepted Manuscript Evaluation of the anti-Acanthamoeba activity of two commercial eye drops commonly used to lower eye pressure Ines Sifaoui, María Reyes-Batlle, Atteneri López-Arencibia, Carolina Wagner, Olfa Chiboub, Jacqueline De Agustino Rodríguez, Pedro Rocha-Cabrera, Basilio Valladares, José E. Piñero, Jacob Lorenzo-Morales PII:

S0014-4894(17)30310-7

DOI:

10.1016/j.exppara.2017.07.012

Reference:

YEXPR 7430

To appear in:

Experimental Parasitology

Received Date: 7 June 2017 Revised Date:

28 June 2017

Accepted Date: 30 July 2017

Please cite this article as: Sifaoui, I., Reyes-Batlle, Marí., López-Arencibia, A., Wagner, C., Chiboub, O., De Agustino Rodríguez, J., Rocha-Cabrera, P., Valladares, B., Piñero, José.E., Lorenzo-Morales, J., Evaluation of the anti-Acanthamoeba activity of two commercial eye drops commonly used to lower eye pressure, Experimental Parasitology (2017), doi: 10.1016/j.exppara.2017.07.012. This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

AC C

EP

TE D

M AN U

SC

RI PT

ACCEPTED MANUSCRIPT

ACCEPTED MANUSCRIPT

Evaluation of the Anti-Acanthamoeba activity of two commercial eye drops

2

commonly used to lower eye pressure

3 4 5 6

Ines Sifaoui 1,2, María Reyes-Batlle 1, Atteneri López-Arencibia 1, Carolina Wagner 1,3, Olfa

7

Chiboub 1,2; Jacqueline De Agustino Rodríguez 1,4 ,Pedro Rocha-Cabrera 1,4, Basilio

8

Valladares 1, José E. Piñero 1, Jacob Lorenzo-Morales 1

9 10 11 12

1

13 14

2

15 16

3

17 18 19 20 21 22

4

RI PT

1

M AN U

SC

University Institute of Tropical Diseases and Public Health, University of La Laguna, Avda Francisco Sanchez s/n, Campus de Anchieta, 38271 la Laguna Tenerife, Canary Islands, Spain.

Laboratoire Matériaux-Molécules et Applications, IPEST, B.P 51 2070, LA Marsa, University of Carthage, Tunisia Catédra de Parasitologia, Facultad de Medicina, Escuela de Bioanalisis, Universidad Central de Venezuela, Caracas, Venezuela

TE D

Department of Ophthalmology, Hospital Universitario de Canarias, Tenerife, Canary Islands, Spain

23

25

Ines Sifaoui

AC C

24

EP

Corresponding author:

26

E-mail: [email protected]

27

Tel: +216 71 740 048

28

ACCEPTED MANUSCRIPT Abstract

30

Efficient treatments against Acanthamoeba Keratitis (AK), remains until the moment, as an

31

issue to be solved due to the existence of a cyst stage which is highly resistant to most

32

chemical and physical agents. In this study, two antiglaucoma eye drops were tested for their

33

activity against Acanthamoeba. Moreover, this study was based on previous data which gave

34

us evidence of a possible link between the absences of Acanthamoeba at the ocular surface in

35

patients treated with beta blockers for high eye pressure both containing timolol as active

36

principle.The amoebicidal activity of the tested eye drops was evaluated against four strains

37

of Acanthamoeba using Alamar blue method. For the most active drug the cysticidal activity

38

against A. castellanii Neff cysts and further experiments studying changes in chromatin

39

condensation levels, in the permeability of the plasmatic membrane, the mitochondrial

40

membrane potential and the ATP levels in the treated amoebic strains were done.

41

Even though both eye drops were active against the different tested strains of Acanthamoeba,

42

statistical analysis revealed that one of them (Timolol Sandoz) was the most effective one

43

against all the tested strains presenting IC50s ranging from 0.529 % ± 0.206 for the CLC 16

44

strain to 3.962 % ± 0.150 for the type strain Acanthamoeba castellanii Neff. Timolol Sandoz

45

0.50% seems to induce amoebic cell death by damaging the amoebae at the mitochondrial

46

level. Considering its effect, Timolol Sandoz 0.50% could be used in the case of contact lens

47

wearers and patients with glaucoma.

48

Keywords: Acanthamoeba; Timolol; Chemotherapy; mechanism of action; mitochondria

AC C

EP

TE D

M AN U

SC

RI PT

29

ACCEPTED MANUSCRIPT Introduction

50

Acanthamoeba is an ubiquitous organism, which has been isolated from several habitats such

51

as soil, water, air, dental unit water among others (1,2). Depending on the external conditions,

52

this organism exists in two different forms: an active, infective trophozoite stage and a highly

53

resistant cyst stage. Acanthamoeba is the causative agent of infections in human such as

54

Acanthamoeba keratitis (AK) and Granulomatous Amoebic Encephalitis (GAE). Moreover,

55

Acanthamoeba keratitis is a serious infection of the cornea that can cause blindness in some

56

cases when not diagnosed and treated early (3,4). Recently, the incidence of AK cases due to

57

Acanthamoeba has shown a remarkable increase worldwide which is mainly related to the

58

increase of contact lens wearers (3-5).

59

Generally, AK, favored by local immunosuppression, is the result of corneal trauma and

60

different factors such as poor hygiene in the handling and storage of the contact lenses and

61

their cases. Currently, the first line treatment regimen for AK includes biguanides [0.02%

62

polyhexamethylene biguanide (PHMB) or 0.02% chlorhexidine digluconate] associated with a

63

diamidine (0.1% propamidine isethionate or 0.1% hexamidine) (4,6). Even though, several

64

studies have been focused on the development of novel therapeutic agents against AK, no

65

fully effective drugs are available at the moment.

66

Recently, Rocha-Cabrera et al., 2015 demonstrated the efficacy of the Schirmer test strips to

67

detect Acanthamoeba at the ocular surface (6). The author reported that most of the patients

68

that were positive for Acanthamoeba did present ocular surface pathologies such as

69

staphylococcal blepharitis, seborrhoeic blepharitis and keratoconjunctivitis sicca. Moreover, it

70

was also observed in this study an absence of Acanthamoeba in patients undergoing treatment

71

for glaucoma or ocular hypertension (data not published). Glaucoma is a neurodegenerative

72

disease considered as the second cause of blindness in the world. Furthermore, in 2020 it is

73

expected that the number of people suffering this disease will reach around 79.6 million (7).

AC C

EP

TE D

M AN U

SC

RI PT

49

ACCEPTED MANUSCRIPT In general, this condition is related to high intraocular pressure (IOP). Beta blockers (beta-

75

adrenergic antagonists) are one of five classes of drugs used to treat glaucoma as they are able

76

to decrease the intraocular pressure (8). In Spain, timolol containing eye drops such as

77

Combigan and Timolol Sandoz 0.5% are drugs often prescribed to treat the IOP.

78

Therefore and based on the previous data mentioned above, this two commercial eye drops

79

used were tested for their activity against Acanthamoeba in the present study.

80

2- MATERIAL AND METHODS

81

2.1- Chemicals

82

Two beta blockers drugs available for topical use against IOP and glaucoma were selected for

83

analysis based on previous data. The drugs included a Timolol (Timolol Sandoz 0.50%) and

84

a mix of Brimonidine tartrate and timolol (Combigan). (see Table 1 for a detailed

85

composition of both eye drops).

86

2.2- In vitro drug sensitivity assay

87

Amoebic strain

88

The amoebicidal activity of the tested eye drops was evaluated against four strains: one type

89

strain from the American Type Culture Collection the Acanthamoeba castellanii Neff (ATCC

90

30010), and three clinical isolates, CLC-16 and Acanthamoeba Griffini, genotype T3 and

91

CLC-51, genotype T1 genotype obtained in a previous studies by Martin Navarro et al., 2008

92

and González-Robles et al., 2014 (9, 10). The strains were axenically grown in PYG medium

93

(0.75% (w/v) proteose peptone, 0.75% (w/v) yeast extract and 1.5% (w/v) glucose)

94

containing 40 µg gentamicin ml−1 (Biochrom AG, Cultek, Granollers, Barcelona, Spain).

95

In vitro effect against the trophozoite stage of Acanthamoeba.

96

The anti-Acanthamoeba activities of the molecules were determined using the Alamar Blue®

97

assay as previously described (9,11). Briefly, Acanthamoeba strains were seeded in duplicate

98

on a 96-well microtiter plate with 50 µl from a stock solution of 104 cells ml−1. Amoebae were

AC C

EP

TE D

M AN U

SC

RI PT

74

ACCEPTED MANUSCRIPT allowed to adhere for 15 min process which was checked using a Leika DMIL inverted

100

microscope (Leika, Wetzlar, Germany). After that, 50 µl of serial dilutions of the fraction

101

tested drugs was added to each well. Finally, the Alamar Blue Assay Reagent® (Biosource,

102

Europe, Nivelles, Belgium) was placed into each well at an amount equal to 10% of the

103

medium volume. Test plates containing Alamar Blue were then incubated for 120 h at 28 °C

104

with a slight agitation.

105

Subsequently, the plates were analyzed, during an interval of time between 72 and 144 h,

106

with an Enspire microplate reader (PerkinElmer, Massachusetts, USA) using a test

107

wavelength of 570 nm and a reference wavelength of 630 nm. Percentages of growth

108

inhibition, 50% and 90% inhibitory concentrations (IC50 and IC90) were calculated by linear

109

regression analysis with 95% confidence limits. All experiments were performed three times

110

each in duplicate, and the mean values were also calculated.

111

Cysticidal activity

112

A. castellanii Neff cysts were prepared as previously described (12). Briefly, trophozoites

113

were transferred from PYG medium based cultures (trophozoite medium) to Neff´s

114

encystment medium (NEM; 0.1 M KCl, 8 mM MgSO4·7H2O, 0.4 mM CaCl2·2H2O, 1 mM

115

NaHCO3, 20 mM ammediol [2-amino-2-methyl-1,3-propanediol; Sigma Aldrich Chemistry

116

Ltd., Madrid, Spain], pH 8.8, at 25 °C) and were cultured in this medium with gently shaking

117

for a week in order to obtain mature cysts. After that, mature cysts were harvested and washed

118

twice using PYG medium.

119

The effects of the active molecules against cysts were evaluated by incubating 104 cysts of A.

120

castellanii Neff with the previously calculated IC90s of the bioactive molecules in PYG

121

medium. The numbers of trophozoites, cysts, and nonviable cysts were counted with a

122

Neubauer chamber at 96, 120, 144, and 168 h.

123

AC C

EP

TE D

M AN U

SC

RI PT

99

ACCEPTED MANUSCRIPT Double-stain assay for apoptosis determination.

125

A double-stain apoptosis detection kit (Hoechst 33342/PI) (GenScript, Piscataway, NJ, USA)

126

and an inverted confocal microscope (Leica DMI 4000B) were used. The experiment was

127

carried out by following the manufacturer’s recommendations, and thus 105 cells/well were

128

incubated in a 24-well plate for 24 h with the previously calculated IC50 and IC90. The double-

129

staining pattern allows the identification of three groups in a cellular population: live cells

130

will show only a low level of fluorescence, apoptotic cells will show a higher level of blue

131

fluorescence, and dead cells will show low-blue and high-red fluorescence (13).

132

Plasma membrane permeability

133

The SYTOX® Green assay was performed to detect the parasite’s membrane permeability

134

alterations. Briefly, 1 × 105 trophozoïtes were washed and incubated in saline water with the

135

SYTOX® Green at a final concentration of 1 µM (Molecular Probes) for 15 min in the dark.

136

Subsequently the compounds were added (IC50s and IC90s). The increase in fluorescence due

137

to binding of the fluorescent marker to the parasite’s DNA was measured using a

138

spectrofluorimeter with excitation filter of 485 nm and emission filter at 520 nm. The reading

139

was normalized by subtracting the baseline fluorescence of the untreated group (negative

140

control) (13,14).

141

Analysis of Mitochondrial Membrane Potential

142

The collapse of an electrochemical gradient across the mitochondrial membrane during

143

apoptosis was measured using a JC-1 mitochondrial membrane potential detection kit (Cell

144

Technology) by flow cytometry as previously described (14, 15). After being treated with IC50

145

and IC90 of the active drug for 24 h, the cells were centrifuged (1000 r.p.m. × 10 min) and

146

resuspended in JC-1 buffer. 100µl of each treated culture was added to a black 96 well plate

147

then 10 µl of JC-1 was added and incubated at 26 °C for 30 min. Analysis for mean green and

148

red fluorescence intensity was done using flow cytometry for 30 minutes .

AC C

EP

TE D

M AN U

SC

RI PT

124

ACCEPTED MANUSCRIPT Measurement of ATP

150

ATP level was measured using a CellTiter-Glo® Luminescent Cell Viability Assay. The

151

effect of the drug on the ATP production was evaluated by incubating (1*105) of cells/ml with

152

the previously calculated IC50 and IC90 of the active drug (14,15).

153

3. Results and discussion

154

Acanthamoeba keratitis is a common condition that can lead to sight-threatening

155

complications and blindness. While the infection rate was reported to be 1.2 per million adults

156

and 0.2–1 per 10,000 contact lens wearers per year (16) rates have recently risen to more than

157

seven-fold in contact lens wearers (17). Acanthamoeba keratitis is often misdiagnosed due to

158

initial non-specific symptoms. At a later stage of the infection, some AK symptom could be

159

developed confirming the infection such as the typical ring infiltrate and radial perineuritis.

160

Nerveless, at this stage the prognosis is guarded and most cases require surgical intervention

161

(4,18).

162

In vitro drug sensitivity assay

163

Both drugs were screened for their activity against the trophozoites stage of different

164

Acanthamoeba strain. From the figure 1, it could be observed that the amoebicidal activity

165

was based on a dependent-dose application. The IC50 and IC90

166

appropriate and comparable data to give as previously described (9,11). The results are

167

illustrated in Table 2.

168

The analysis of variance by Multifactor ANOVA, illustrated that the biological activity was

169

strain dependent with p = 0.0001 < 0.001. In fact, the CLC51 was the most sensitive strain to

170

both drugs with an IC50 ranged 1.243 % ± 0.103 for TS and 2.715 % ± 0.007 for Combigan.

171

With 3.125% of Timolol Sandoz a few trophozoïtes of CLC51 were observed as shown in

172

figure 2. Meanwhile, A. Neff and A. griffini were the most resistant strains to both drugs. On

173

the other hand, the effect of drug type was statistically significant on the activity since the p =

at

/96 h were chosen as the

AC C

EP

TE D

M AN U

SC

RI PT

149

ACCEPTED MANUSCRIPT 0.0000 < 0.001, the Timolol Sandoz was the most effective drugs against all the strains with

175

the IC50 ranged from 0.529 % ± 0.206 for the CLC 16 until 3.962 % ± 0.150 for A. Neff.

176

Figure 3 showed that up to 120h the excystation did not occur with all the tested drugs. In

177

fact, 4,5 % of the Timolol Sandoz could inhibit 50% of the initial inoculums in cysts,

178

meanwhile, at 40% the same drug was able to inhibit 90% of the cysts.

179

Timolol treated cells stained positive in the double-stain assay. When double staining was

180

performed, the tested drug at both concentration IC50 and IC90 caused nuclei staining with

181

Hoechst, indicating the presence of condensed chromatin (Fig. 4). Moreover, the differences

182

between the three cell populations were clear, and thus live cells were detected under

183

fluorescence microscopy, as they showed faint-blue nuclei, whereas cells displaying PCD

184

presented bright-blue nuclei due to chromatin condensation. Meanwhile, the nuclei of cells

185

treated with the IC90 showed a double stain blue and red demonstrating a late stage of PCD.

186

Timolol Sandoz caused plasma membrane permeability in treated cells. As shown in

187

Figure 5.D, amoebae treated with both concentrations IC50 and IC90 of the tested drug induced

188

cellular membrane damage after 30 min of treatment. Nevertheless, cellular membrane

189

disruption and the cell integrity was checked and confirmed using fluorescence microscopy in

190

treated cells (Fig. 5 A to C).

191

Timolol Sandoz induced mitochondrial malfunction. As it can be observed in figure 6,

192

histograms of the mitochondrial potential fluorescence demonstrated that the treatment with

193

the IC50 and IC90, decreased the membrane potential (∆Ψm) of A.Neff by 28%, 75%,

194

respectively.

195

generation in 24h. We found that both concentrations produced a pronounced decrease in the

196

total ATP level (Figure 7). In fact, cells treated with the IC90 generated a percentage of ATP

197

less than 80% of the untreated cells.

AC C

EP

TE D

M AN U

SC

RI PT

174

The mitochondrial damage has been confirmed with the measure of ATP

ACCEPTED MANUSCRIPT Glaucoma constitutes the second-leading cause of blindness in the world. Furthermore, in

199

2020 the number of people affected by this illness could exceed the 79 million (7).

200

Keratoplasty in eyes with glaucoma are high-risk procedures and glaucoma has to be

201

monitored more efficiently pre- and postoperatively. Combigan and Timolol Sandoz are

202

beta blockers drugs used against IOP and Glaucoma. Both drugs present an amoebicidal

203

activity against trophozoite and cyst, although Timolol Sandoz exhibits a stronger activity

204

against the four strains. Furthermore, this drug contains 0.01% of preservative agent the

205

benzalkonium chloride. Sunada et al., (2014) have reported the effectiveness of this

206

preservative on several Acanthamoeba strains by altering membrane permeability and the

207

formation of pseudocyst (19). Even though, Benzalkonium chloride has the highest

208

effectiveness among the preservative agents, its toxicity to the human cornea needs to be

209

considered (19). During our study, the amount of Benzalkonium chloride used in well is less

210

than 0.001%. Niszl & Markus, (1998) reported that eye drop containing 0.004% of BAK are

211

not efficient to kill Acanthameoba cysts (20). Several reports confirmed the important role of

212

phospholipases in Acanthamoeba virulence (4, 21). The timolol maleate, Timolol Sandoz’s

213

active ingredient, is a beta blocker that could inhibit the production of phospholipase secreted

214

by Acanthamoeba as reported by Hänel et al, (1995). In fact, those authors demonstrated that

215

the inhibition of Candida albicans by blocker-like structures was mainly due to the decrease

216

of phospholipase secretion (22).

217

Programmed Cell Death or apoptosis has been described in unicellular protists and in

218

multicellular

219

morphological characteristics namely the chromosomal condensation, nuclear DNA

220

fragmentation, cell shrinkage, loss of mitochondrial membrane potential, the formation of

221

apoptotic bodies, and the externalization of phosphatidylserine (23, 24).

AC C

EP

TE D

M AN U

SC

RI PT

198

organisms.

This

process

is

generally

characterized

by

distinct

ACCEPTED MANUSCRIPT Apoptosis has been already described in Acanthamoeba (T4) by Feng et al., (2009) (25). The

223

authors observed that the PCD occurred 6 h after infection with Salmonella Typhimurium.

224

Furthermore, the death pathway was confirmed by detection of phosphatidylserine

225

externalization and chromatin condensation in A. rhysodes. Recently, evidence of apoptosis in

226

Acanthamoeba species has been described by Nakisah et al., (2012) (26) and Martin- Navarro

227

et al., (2015) (13). Both reports distinguish between early apoptotic cells, late apoptotic cells,

228

and necrotic cells by observing chromatin condensation. In our study, the Timolol Sandoz at

229

IC50 induced chromatin condensation confirmed by the blue fluorescence. While treating with

230

the IC90 the cells were double stain, (Red and blue) indicating late apoptosis.

231

The possible action of the tested drug on the cell membrane was studied using the fluorescent

232

probe SYTOX Green. Our data indicated that the membrane damage occurs immediately after

233

the contact with the tested molecules. Even though, the timolol could permeabilize the

234

cytoplasmic membrane, the microscopic observation confirmed maintenance of the cell’s

235

shape. Due to its low weight, the timolol maleate could get inside the cells without necrosis

236

effects (27).

237

In case of malfunction of the mitochondria and especially its membrane potential the cells

238

stop synthesizing ATP, leading to Programmed Cell Death (28). In the present study, The

239

Timolol Sandoz produced a pronounced decrease in the mitochondrial potential and therefore

240

in the total ATP level. It’s likely that those drugs could induce apoptosis in Acanthamoeba

241

cells through the intrinsic pathway.

242

Conclusion

243

In conclusion, the obtained results suggest that Timolol Sandoz possess an interesting

244

amoebicidal activity. Considering the observed effects on the mitochondria function by

245

decreasing both the mitochondrial potential and the ATP content, this drug seem to induce

246

apoptosis via the mitochondria pathway. Although, further studies are necessary in order to

AC C

EP

TE D

M AN U

SC

RI PT

222

ACCEPTED MANUSCRIPT validate this hypothesis by studying characteristic signals of this pathway such as ROS

248

generation and DNA fragmentation. Finally, therapy using Timolol Sandoz 0.50% could be

249

considered in the case of contact lens wearers and patients with glaucoma to prevent

250

Acanthamoeba keratitis. Nevertheless, further in vitro and in vivo studies should be

251

developed.

252

Acknowledgments

253

This work was supported by the grants RICET (project no. RD06/0021/0005 of the

254

programme of Redes Temáticas de Investigación Cooperativa, FIS), Spanish Ministry of

255

Health, Madrid, Spain and the Project FIS PI10/01298 “Protozoosis emergentes por amebas

256

de vida libre: aislamiento y caracterización molecular, identificación de cepas transportadoras

257

de otros agentes patógenos y búsqueda de quimioterapias efectivas and PI13/00490

258

“Protozoosis Emergentes por Amebas de Vida Libre: Aislamiento, Caracterización, Nuevas

259

Aproximaciones Terapéuticas y Traslación Clínica de los Resultados” from the Instituto de

260

Salud Carlos III. IS and ALA were funded by the Agustín de Betancourt Programme. JLM

261

was funded by Ayudas Proyectos Puente de la Universidad de La Laguna 2017.

AC C

EP

TE D

M AN U

SC

RI PT

247

ACCEPTED MANUSCRIPT References

263

1. Marciano-Cabral F, Cabral G. Acanthamoeba spp. as agents of disease in humans. Clin

264

Microbiol Rev. 2003;16:273-307.

265

2. Siddiqui R, Khan NA. Biology and pathogenesis of Acanthamoeba. Parasit Vectors. 2012;

266

5(6).

267

3. Lorenzo-Morales J, Martín-Navarro C. M, López-Arencibia A, Arnalich-Montiel F, Piñero,

268

J. E, Valladares, B. Acanthamoeba keratitis: an emerging disease gathering importance

269

worldwide?. Trends Parasitol. 2013; 29(4), 181-187.

270

4. Lorenzo-Morales J, Khan N. A, Walochnik J. An update on Acanthamoeba keratitis:

271

diagnosis, pathogenesis and treatment. Parasite. 2015; 22, 10.

272

5. Kettesy B, Kemeny-Beke A, Berta A, Modis Jr L. (2012). Keratoplasty in contact lens

273

related Acanthamoeba keratitis. INTECH Open Access Publisher.

274

6. Rocha-Cabrera P, Reyes-Batlle M, Martín-Navarro C. M, Dorta-Gorrín A, López-

275

Arencibia A, Sifaoui, I, et al. Detection of Acanthamoeba on the ocular surface in a Spanish

276

population using the Schirmer strip test: pathogenic potential, molecular classification and

277

evaluation of the sensitivity to chlorhexidine and voriconazole of the isolated Acanthamoeba

278

strains. J Med Microbiol. 2015; 64(8), 849-853.

279

7. Andrés-Guerrero V, Vicario-de-la-Torre M, Molina-Martínez I. T, Benítez-del-Castillo J.

280

M, García-Feijoo J, Herrero-Vanrell R. Comparison of the in vitro tolerance and in vivo

281

efficacy of traditional timolol maleate eye drops versus new formulations with bioadhesive

282

polymers. Invest Ophthalmol Vis Sci. 2011; 52(6), 3548-3556.

283

8. Bagnis A, Papadia M, Scotto R., Traverso, C. E. Current and emerging medical therapies in

284

the treatment of glaucoma. Expert Opin Emerg Drugs. 2011; 16(2), 293-307.

285

9. Martín-Navarro CM, Lorenzo-Morales J, Cabrera-Serra MG, Rancel F, Coronado-Álvarez

286

NM, Piñero JE, et al. The potential pathogenicity of chlorhexidine-sensitive Acanthamoeba

AC C

EP

TE D

M AN U

SC

RI PT

262

ACCEPTED MANUSCRIPT strains isolated from contact lens cases from asymptomatic individuals in Tenerife, Canary

288

Islands, Spain. J Med Microbiol. 2008 ;57: 1399–1404.

289

10. González-Robles A, Salazar-Villatoro L, Omaña-Molina M, Reyes-Batlle M, Martín-

290

Navarro C. M, Lorenzo-Morales J. Morphological features and in vitro cytopathic effect of

291

Acanthamoeba griffini trophozoites isolated from a clinical case. J Parasitol Res. 2014. doi:

292

10.1155/2014/256310.

293

11. McBride J, Ingram PR, Henríquez FL. Development of colorimetric microtiter plate assay

294

for assessment of antimicrobials against Acanthamoeba. J Clin Microbiol. 2005; 43: 629–634.

295

12. Martín-Navarro C. M, López-Arencibia A, Arnalich-Montiel F, Valladares B, Piñero J. E,

296

Lorenzo-Morales, J. Evaluation of the in vitro activity of commercially available

297

moxifloxacin and voriconazole eye-drops against clinical strains of Acanthamoeba. Ger

298

J Ophthalmol. 2013; 251(9), 2111-2117.

299

13. Martín-Navarro C. M, López-Arencibia A, Sifaoui I, Reyes-Batlle M, Valladares B,

300

Martínez-Carretero E, et al. (2015). Statins and Voriconazole Induce Programmed Cell Death

301

in Acanthamoeba castellanii. Antimicrob. Agents Chemother. 2015; 59(5), 2817-2824.

302

14. Sifaoui, I, López-Arencibia A, Martín-Navarro C. M, Ticona J. C, Reyes-Batlle M, Mejri

303

M, et al. In vitro effects of triterpenic acids from olive leaf extracts on the mitochondrial

304

membrane potential of promastigote stage of Leishmania spp. Phytomedicine. 2014; 21(12),

305

1689-1694.

306

15. López-Arencibia A, García-Velázquez D, Martín-Navarro C. M, Sifaoui I, Reyes-Batlle

307

M, Lorenzo-Morales J, et al. In vitro activities of hexaazatrinaphthylenes against Leishmania

308

spp. Antimicrob. Agents Chemother. 2015; 59(5), 2867-2874.

309

16. Matsumoto Y, Dogru M, Sato E. A, Katono Y, Uchino Y, Shimmura S, Tsubota K. The

310

application of in vivo confocal scanning laser microscopy in the management of

311

Acanthamoeba keratitis. Mol Vis. 2007; 13(7), 1319-1326.

AC C

EP

TE D

M AN U

SC

RI PT

287

ACCEPTED MANUSCRIPT 17. Labbé A, Khammari C, Dupas B, Gabison E, Brasnu E, Labetoulle M, Baudouin C.

313

Contribution of in vivo confocal microscopy to the diagnosis and management of infectious

314

keratitis. Ocul Surf. 2007; 7(1), 41-52.

315

18. Villani E, Baudouin C, Efron N, Hamrah P, Kojima T, Patel S. V, et al. In vivo confocal

316

microscopy of the ocular surface: from bench to bedside. Current eye research. 2014; 39(3),

317

213-231.

318

19. Sunada, A., Kimura, K., Nishi, I., Toyokawa, M., Ueda, A., Sakata, T., et al. (2014). In

319

vitro evaluations of topical agents to treat Acanthamoeba keratitis. Ophthalmology, 121(10),

320

2059-2065.

321

20. Niszl I. A, Markus, M. B. Anti-Acanthamoeba activity of contact lens solutions. Br. J.

322

Ophthalmol. 1998; 82(9), 1033-1038.

323

21. Khan, N. A. (2009). Acanthamoeba: biology and pathogenesis. Horizon Scientific Press.

324

22. Hänel H, Kirsch R, Schmidts H. L, Kottmann H. New systematically active antimycotics

325

from the beta‐blocker category. Mycoses. 1995. 38(7‐8), 251-264.

326

23. Elmore, S. Apoptosis: a review of programmed cell death. Toxicol. Pathol. 2007; 35(4),

327

495-516.

328

24. Kaczanowski S, Sajid M, Reece SE. Evolution of apoptosis-like programmed cell death in

329

unicellular protozoan parasites. Parasit Vectors; 2011; 4 : 44.

330

25. Feng Y, Hsiao Y. H, Chen H. L, Chu C, Tang P, Chiu, C. H. Apoptosis-like cell death

331

induced by Salmonella in Acanthamoeba rhysodes. Genomics. 2009; 94(2), 132-137.

332

26. Nakisah, M. A., Muryany, M. I., Fatimah, H., Fadilah, R. N., Zalilawati, M. R., Khamsah,

333

S., & Habsah, M. (2012). Anti-amoebic properties of a Malaysian marine sponge Aaptos sp.

334

on Acanthamoeba castellanii. World Journal of Microbiology and Biotechnology, 28(3),

335

1237-1244.

AC C

EP

TE D

M AN U

SC

RI PT

312

ACCEPTED MANUSCRIPT 27. Hsieh YJ, Wu CC, Chang CJ, Yu JS. Subcellular localization of Photofrin determines the

337

death phenotype of human epidermoid carcinoma A431 cells triggered by photodynamic

338

therapy: when plasma membranes are the main targets. J Cell Physiol. 2003 ;194 :363-75.

339

28. Joshi DC, Bakowska JC. Determination of mitochondrial membrane potential and reactive

340

oxygen species in live rat cortical neurons. J Vis Exp. 2011; 51: 2704.

RI PT

336

AC C

EP

TE D

M AN U

SC

341

ACCEPTED MANUSCRIPT Figure Captions

342 343

Figure 1. Effects of (a) Timolol Sandoz 0.50% and (b) Combigan against different

345

strains of Acanthamoeba strains.

346

Figure 2: Effect of the Timolol Sandoz 0.50% against CLC51 observed by inverted

347

microscopy (x20). a. Timolol Sandoz at 50% absence of trophozoites or cysts. b. Timolol

348

Sandoz at 3.125% few trophozoites were observed. c. Negative control

349

Figure 3: Effects of Timolol Sandoz against cysts were evaluated by incubating 104 cysts of

350

A. castellanii Neff with the previously calculated IC50 and IC90 values of the selected drugs in

351

PYG medium, and cells were counted with a Neubauer chamber at between 24 and 120 h.

352

Number of cysts that reverted to trophozoites in PYG medium after incubation with the drugs.

353

Number of nonviable cysts when cysts were incubated with the previously calculated IC50 and

354

IC90 in PYG medium.

355

Figure 4: Hoechst staining is different in control cells, where uniformly faint-blue nuclei are

356

observed, and in treated cells, where the nuclei are bright blue. (A to C) Overlay images:

357

control (24 h) (A), Timolol Sandoz IC50 (24 h) (B), Timolol Sandoz IC90 (24 h). (D to F)

358

Hoechst channel: control (24 h) (D), Timolol Sandoz IC50 (24 h) (E), Timolol Sandoz IC90 (24

359

h) (F). (G to I) Propidium iodine channel: control (24 h) (G), Timolol Sandoz IC50 (24 h) (H),

360

Timolol Sandoz IC90 (24 h) (I). (Magnification of 64x).

361

Figure 5: Permeabilization of the cellular membrane. Fluorescence from the Sytox green

362

nucleic acid stain can be observed when cells were treated with the different treatments after 2

363

h. (A) Control; (B) Timolol Sandoz at IC50; (C) Timolol Sandoz at IC90. (D) Differences

364

between Negative control and the drug-treated cells were apparent when fluorescence of the

365

cells was measured. (Magnification of 64x)

AC C

EP

TE D

M AN U

SC

RI PT

344

ACCEPTED MANUSCRIPT Figure 6: Mitochondrial membrane potential (∆ψm) Showing change in the Ratio of

367

fluorescence intensity at 590/530 nm after the 24 hours of treatment with the IC50 and IC90 of

368

the tested drug. Results are representing in percentage relative to the negative control.

369

Figure 7: The effect of both molecules on the ATP content, using CellTiter-Glo®

370

Luminescent Cell Viability Assay. Results are representing in percentage relative to the

371

negative control. Cells were treated by the IC50 and IC90 concentration for 24 hours.

RI PT

366

AC C

EP

TE D

M AN U

SC

372

ACCEPTED MANUSCRIPT Table 1. Detailed composition of the tested drugs Combigan 

-

Brimonidina taratrato 2mg/ml

Timolol 5 mg/ml

Timolol 5 mg/ml

benzalkonium chloride 0.01%

benzalkonium chloride 0.005%

Disodium phosphate dodecahydrate

Sodium phosphate monobasic monohydrate

Sodium phosphate dihydrate

Fosfato sodico dibasico heptahidratado

AC C

EP

TE D

M AN U

SC

RI PT

Timolol Sandoz 0.5%

ACCEPTED MANUSCRIPT Table 2. Antiamoebic activity of the tested drugs against Acanthamoeba spp

Combigan

Timolol Sandoz 0.5

BT (mg/ml)

T (mg/ml)

%

T (mg/ml)

IC50

5.305 ± 0.153

0.106 ±0.004

0.265 ± 0.009

3.962 ± 0.150

0.198 ±0.008

IC90

11.378 ±1.085

0.227± 0.022

0.568 ± 0.054

IC50

5.187 ± 0.274

0.104 ± 0.007

0.260 ± 0.018

IC90

9.555 ± 0.091

0.191 ± 0.001

0.478 ± 0.004

IC50

2.715 ± 0.007

0.054 ± 0.002

0.136 ± 0.007

IC90

4.853 ± 0.000

0.097 ± 0.000

0.243 ± 0.003

2.917 ± 0.013

0.146 ± 0.000

IC50

5.063 ±0.291

0.101± 0.006

0.253 ± 0.015

0.529 ± 0.206

0.188 ± 0.005

IC90

9.941 ± 0.154

0.199 ± 0.003

5.708 ± 0.154

0.446 ±0.001

A. Neff

AC C

EP

TE D

CLC16

M AN U

CLC51

8.384 ± 0.185

0.420 ± 0.054

3.628 ± 0.274

0.182 ± 0.014

7.604 ± 0.091

0.380 ± 0.004

1.243 ± 0.103

0.062 ± 0.005

SC

A. griffini

RI PT

%

0.497 ± 0.008

ACCEPTED MANUSCRIPT 100

Timolol Sandoz vs A. Neff Timolol Sandoz vs A. Griffini Timolol Sandoz vs CLC 51 Timolol Sandoz vs CLC16

RI PT

60

40

20

0

10

20

30

40

M AN U

0

SC

Gowth inhibition (%)

80

a

50

60

Drug percentage (%)

60

0

vs A. Neff vs A. Griffini vs CLC 51 vs CLC 16

EP

40

20

Combigan Combigan Combigan Combigan

TE D

80

AC C

Growth inhibition (%)

100

0

10

b 20

30

Drug percentage (%)

Figure 1

40

50

60

ACCEPTED MANUSCRIPT

SC

RI PT

a

AC C

EP

c

TE D

M AN U

b

Figure 2

ACCEPTED MANUSCRIPT

Trophozoite negative controle Trophozoite treated with Timolol Sandoz IC50 Unviable cyst Timolol Sandoz IC50 trophozoite treated with Timolol Sandoz IC90 Unviable cyst Timolol Sandoz IC90

60000 50000

RI PT

30000 20000 10000

SC

2000 0

0

20

M AN U

-2000 40

60

Time (hours)

EP

TE D

Figure 3

AC C

Number of cells/ ml

40000

80

100

120

140

TE D

M AN U

SC

RI PT

ACCEPTED MANUSCRIPT

AC C

EP

Figure 4

M AN U

SC

RI PT

ACCEPTED MANUSCRIPT

AC C

EP

TE D

Figure 5

AC C EP TE D M AN U

Timolol IC 50

20

0

Timolol IC 90

RI PT

Figure 6

SC

Mitochondrial potential % relative to controle

ACCEPTED MANUSCRIPT

80

60

40

ACCEPTED MANUSCRIPT

80

60

RI PT

ATP level % relative to the controle

100

40

20

Timolol IC50

Timolol IC90

AC C

EP

TE D

M AN U

Figure 7

SC

0

ACCEPTED MANUSCRIPT Highlights

RI PT

- The anti-amoebic activity of two beta blockers eye drops was evaluated - Timolol Sandoz was the most effective drugs against all the Acanthamoeba strains - Timolol Sandoz decrease the mitochondrial membrane potential to less than 75%

AC C

EP

TE D

M AN U

SC

- The PCD was induced by the collapse of the mitochondrial membrane potential